Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Bartholow, Tanner L ^a   Chandran, Uma R ^a   Becich, Michael J ^a   Parwani, Anil V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 3; MEMBRANE PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BIOPSY; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN MICROARRAY;

ADENOCARCINOMA; BIOPSY; HUMANS; MALE; MEMBRANE PROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651558301     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-12     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005, 174(5):1785-1788. discussion 1788, 10.1097/01.ju.0000177470.84735.55, 16217287.
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977, 20(5):680-688. 10.1002/ijc.2910200506, 924691.
4. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980, 14(1):29-35. 10.3109/00365598009181186, 6154966.
5. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982, 29(6):611-616. 10.1002/ijc.2910290602, 7107064.
6. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94(13):981-990.
7. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005, 5:45. 10.1186/1471-2407-5-45, 1173092, 15892885.
8. Tsukita S, Furuse M. The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci 2000, 915:129-135. 10.1111/j.1749-6632.2000.tb05235.x, 11193568.
9. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006, 68:403-429. 10.1146/annurev.physiol.68.040104.131404, 16460278.
10. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2(4):285-293. 10.1038/35067088, 11283726.
11. Cereijido M, Shoshani L, Contreras RG. Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol 2000, 279(3):G477-482.
12. Cereijido M, Valdes J, Shoshani L, Contreras RG. Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol 1998, 60:161-177. 10.1146/annurev.physiol.60.1.161, 9558459.
13. D'Atri F, Citi S. Molecular complexity of vertebrate tight junctions (Review). Mol Membr Biol 2002, 19(2):103-112.
14. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65(21):9603-9606. 10.1158/0008-5472.CAN-05-2782, 16266975.
15. Ouban A, Ahmed AA. Claudins in human cancer: a review. Histol Histopathol 25(1):83-90.
16. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000, 60(22):6281-6287.
17. Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 2007, 22(11):1185-1195.
18. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006, 6:186. 10.1186/1471-2407-6-186, 1538620, 16836752.
19. Soini Y, Kinnula V, Kahlos K, Paakko P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 2006, 59(3):250-254. 10.1136/jcp.2005.028589, 1860350, 16505274.
20. Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol 2008, 21(11):1320-1329. 10.1038/modpathol.2008.116, 18587324.
21. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007, 38(4):564-569. 10.1016/j.humpath.2006.11.007, 17306334.
22. Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, et al. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 2007, 38(2):113-121. 10.1007/s10735-006-9054-5, 17318343.
23. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol 2007, 2:41. 10.1186/1746-1596-2-41, 2174437, 17963516.
24. Seo KW, Kwon YK, Kim BH, Kim CI, Chang HS, Choe MS, Park CH. Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer. Korean J Urol 51(4):239-244. 10.4111/kju.2010.51.4.239, 2858850, 20428425.
25. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer 2008, 99(3):491-501. 10.1038/sj.bjc.6604486, 2527792, 18648369.
26. Nakanishi K, Ogata S, Hiroi S, Tominaga S, Aida S, Kawai T. Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract. Am J Clin Pathol 2008, 130(1):43-49. 10.1309/U77A6BTEXVCA5D0E, 18550469.
27. Jung H, Jun KH, Jung JH, Chin HM, Park WB. The Expression of Claudin-1, Claudin-2, Claudin-3, and Claudin-4 in Gastric Cancer Tissue. J Surg Res
28. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003, 9(7):2567-2575.
29. D'Souza T, Agarwal R, Morin PJ. Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 2005, 280(28):26233-26240.
30. Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005, 65(16):7378-7385. 10.1158/0008-5472.CAN-05-1036, 16103090.
31. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 2001, 61(21):7878-7881.
32. Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007, 109(7):1312-1322. 10.1002/cncr.22536, 17326053.